文献速递眼底病与葡萄膜炎

非感染性中间、后或全葡萄膜炎中糖皮质激素相关不良事件随糖皮质激素剂量系统性增加:VISUAL-1和VISUAL-2试验的事后分析

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
PubMed 文献 · Ophthalmology · 2017-07-06

该研究对VISUAL-1和VISUAL-2安慰剂对照试验进行事后分析,仅纳入安慰剂组成人非感染性中间、后或全葡萄膜炎患者,评估糖皮质激素剂量与激素相关不良事件发生率的关系。结果显示,泼尼松治疗期间激素相关不良事件发生率显著高于停药后,且泼尼松剂量每增加10 mg,激素相关不良事件发生率在VISUAL-1和VISUAL-2分别增加1.5倍和2.6倍。

要点

  • VISUAL-1安慰剂组泼尼松治疗期间激素相关不良事件发生率为454.2/100患者年,停药后为36.1/100患者年,发生率比=12.6,P<0.001。
  • VISUAL-2安慰剂组泼尼松治疗期间激素相关不良事件发生率为317.5/100患者年,停药后为41.1/100患者年,发生率比=7.7,P<0.001。
  • 泼尼松剂量每增加10 mg,激素相关不良事件发生率在VISUAL-1增加1.5倍,在VISUAL-2增加2.6倍(均P<0.001)。

核心结论

  • VISUAL-1和VISUAL-2的证据提示,激素相关不良事件的发生率随糖皮质激素剂量系统性增加。

研究设计与样本

  • VISUAL-1和VISUAL-2安慰剂对照临床试验的事后分析,纳入患有活动性(VISUAL-1)和非活动性(VISUAL-2)非感染性中间、后和全葡萄膜炎的成人。
  • 患者被随机分配接受阿达木单抗或安慰剂,并接受方案规定的强制逐渐减量以停用口服糖皮质激素;本分析仅考虑随机分配至安慰剂的患者。
  • 每次访视收集不良事件数据,包括研究者对激素相关性的评估;采用纵向泊松回归模型,控制时变糖皮质激素剂量、年龄、性别、既往口服糖皮质激素剂量、既往局部糖皮质激素使用和合并免疫抑制药物使用。

主要发现

  • VISUAL-1安慰剂组泼尼松治疗期间激素相关不良事件发生率为454.2/100患者年,停药后为36.1/100患者年,发生率比=12.6,P<0.001。
  • VISUAL-2安慰剂组泼尼松治疗期间激素相关不良事件发生率为317.5/100患者年,停药后为41.1/100患者年,发生率比=7.7,P<0.001。
  • 基于泊松多变量纵向广义估计方程(GEE)模型,泼尼松剂量每增加10 mg,激素相关不良事件发生率在VISUAL-1增加1.5倍(P<0.001),在VISUAL-2增加2.6倍(P<0.001)。
  • 活动性葡萄膜炎患者每日服用泼尼松60 mg与每日10 mg相比,平均每年额外发生10.1例(95%CI 6.3-14.5;P<0.001)激素相关不良事件。
  • 非活动性葡萄膜炎患者每日服用泼尼松35 mg与每日10 mg相比,平均每年额外发生23.5例(95%CI 7.6-52.7;P=0.05)激素相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs). This study examines the association between corticosteroid dosage and incidence rates of corticosteroid-related AEs. DESIGN: A post hoc analysis of the VISUAL-1 and VISUAL-2 placebo-controlled clinical trials. PARTICIPANTS: The clinical trials consisted of adults with active (VISUAL-1) and inactive (VISUAL-2) noninfectious intermediate, posterior, and panuveitis. Patients were randomized to receive adalimumab or placebo and underwent a protocol-defined mandatory taper to discontinue their oral corticosteroids. METHODS: Adverse event data were collected at each visit and included an assessment of the corticosteroid relationship by the investigator. A longitudinal Poisson regression model was estimated controlling for time-dependent corticosteroid dose, age, sex, prior oral corticosteroid dose, prior topical corticosteroid use, and concomitant immunosuppressive drug use. Only patients randomized to placebo were considered. MAIN OUTCOME MEASURES: The primary outcome measure was the frequency of AEs. RESULTS: The incidence rates of corticosteroid-related AEs among placebo patients during the prednisone treatment period in VISUAL-1 was statistically higher than after discontinuation (454.2 per 100 patient-years [PY] vs. 36.1 per 100 PY, incident rate ratio = 12.6, P < 0.001). Incidence rate ratios among VISUAL-2 patients were similarly high (317.5 per 100 PY vs. 41.1 per 100 PY, incident rate ratio = 7.7, P < 0.001). Based on the Poisson multivariate longitudinal Generalized Estimating Equation (GEE) model, each 10 mg increase in prednisone dose is associated with a 1.5- and 2.6-fold increase (P < 0.001 and P < 0.001) in the rate of corticosteroid-related AEs in VISUAL-1 and VISUAL-2, respectively. This implies in turn that a patient with active uveitis taking 60 mg/day of prednisone will experience, on average, an additional 10.1 (95% confidence interval (CI), 6.3-14.5; P < 0.001) corticosteroid-related AEs per year compared with a patient taking 10 mg/day, whereas a patient with inactive uveitis taking 35 mg/day of prednisone will experience, on average, an additional 23.5 (95% CI, 7.6-52.7; P = 0.05) corticosteroid-related AEs per year compared with a patient taking 10 mg/day. CONCLUSIONS: Evidence from VISUAL-1 and VISUAL-2 suggests that the incidence rates of corticosteroid-related AEs increase systematically with corticosteroid dose.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Suhler EB, Thorne JE, Mittal M, et al. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. Ophthalmology. 2017. PMID: 28689898. doi:10.1016/j.ophtha.2017.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。